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1. Introduction 
Patients with multiple myeloma (MM) are increasingly at risk for thromboembolic events 
(TEEs), usually venous thromboembolism (VTE) [1]. The introduction of thalidomide and 
lenalidomide has clearly improved outcomes in MM patients but these immunomodulatory 
agents (IMiDs) are also associated with higher rates of TEEs [2]. The pathogenesis of 
thalidomide/lenalidomide-associated thrombosis is multifactorial and poorly understood. 
Patients with MM who are being treated with schemes including combinations of either 
thalidomide or lenalidomide plus other agents should receive some form of thrombosis 
prophylaxis [3]. This chapter discusses the incidence, pathogenic mechanisms, prophylaxis 
and treatment of thalidomide/lenalidomide-associated TEEs. 
2. Multiple myeloma and thrombosis 
The risk of developing venous thrombotic complications for patients with cancer is 
approximately five times that of the general population (0.5 vs. 0.1%) [4]. Multiple myeloma 
(MM), characterized by the malignant proliferation of clonal plasma cells, accounts for 
approximately 10% of hematologic malignancies and affects older individuals (median age, 
70 years) [5]. Thromboembolic events are a key concern in clonal plasma cells disorders, 
such as monoclonal gammopathy of undetermined significance (MGUS) as well as in MM. 
The exact incidence of VTE in MGUS is difficult to determine since reported VTE rates 
probably vary according to the level of diagnostic vigilance. The underlying medical 
problems that prompted laboratory testing for monoclonal may also increase the risk of 
VTE. Srkalovic et al [1] noted an increased incidence of VTE among patients with MGUS. 
They reported that 7.5% (13 of 174 patients) of patients with MGUS developed VTE at a 
median of 4 months (range, 0–67 months) after diagnosis. The cumulative VTE rate was 16% 
after 8 years of follow-up. A medical history of VTE, family history of VTE, immobility, low 
serum albumin level and an increase in leukocyte count were found to be correlated with 
increased incidence of VTE in patients with MGUS. In another retrospective study (310 
patients with MGUS) the incidence of VTE was 6.1% after a median follow-up of 44 months 
[6]. Univariate analysis showed that age ≥ 65 years, M protein ≥ 16 g/l and disease 
progression to symptom MM were the significant risk factors for VTE. A retrospective 
review of U.S. Veterans Affairs hospital records from 1980–1996 reported an incidence of 
VTE of 0.9, 3.1 and 8.7% in veterans without a plasma cell dyscrasia, diagnosed to have 
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MGUS, and MM, respectively [7]. The incidence of VTE in MM patients is difficult to 
estimate and varies from 3–10%. On the other hand, the recent introduction of the anti-
myeloma therapy class called immunomodulatory drugs (IMiDs), substantially increased 
risk of VTE in multiple myeloma. 
The exact pathogenesis of thrombosis in plasma cell dyscrasia is multifactorial and poorly 
understood. Prothrombotic coagulation abnormalities are found in patients with newly 
diagnosed multiple myeloma, including elevated levels of von Willebrand antigen factor, 
factor VIII and tissue factor, as well as decreased protein S and thrombosposndin [8]. 
Proinflammatory and angiogenic cytokines such as interleukin-6, tumor necrosis factor and 
vascular endothelial growth factor (VEGF) are elevated in MM and could activate the 
coagulation system [9]. A recently described mechanism of hypercoagulability in cancer 
patients, including MM patients, is acquired activated protein C resistance (APC-R). APC-R, 
in the absence of factor V Leiden mutation, was present in almost one-quarter of newly 
diagnosed myeloma patients and significantly increased the risk of VTE [10]. The possible 
production of auto-antibodies against protein C in these patients could explain the transient 
APC resistance phenotype. However, to date, we know of no single prothrombotic 
abnormality that can be used to predict which patients with plasma cell dyscrasia will 
develop VTE. Other risk factors of MM-associated thrombosis are involved, such as older 
age, immobility, prior or family history of VTE and the presence of other medical 
comorbidities, immobility due to pain and/or surgery, indwelling central venous catheters, 
extrinsic venous compression by plasmacytomas, and the presence of inherited factors such 
as factor V Leiden. However, the dominant risk factor for VTE in MM is the type of drug 
administered.  
3. Thalidomide and thrombosis 
Thalidomide is a glutamic acid derivative that exerts potent anti-angiogenic and 
immunomodulatory activity and has revolutionized clinical management of patients with 
myeloma. Thalidomide is effective in relapsed or refractory and newly diagnosed MM. 
However, from experience with myeloma patients, VTE has recently emerged as the single 
most important complication. The anti-myeloma effect is mediated by several mechanisms 
in myeloma cells directly as well as by the microenvironment [11]. Thalidomide induces G1 
growth arrest/apoptosis by inhibiting NF-ΚB [12] and activating caspase. It inhibits 
adhesion of myeloma cells to bone marrow stromal cells, and inhibits secretion of cytokines 
(VEGF, [13], βFGF, [14-16], HGF, [17], TNFa, [18], IL-6, [19] and soluble IL-6 receptor (sIL-
6R) [20]); up-regulate ICAM-1, [21] VCAM-1, IL-10, [22-23] and IL-12, [24]. Finally, it 
induces T cell and NK cell anti-myeloma immunity and inhibits angiogenesis [25]. 
The occurrence of VTE with the use of thalidomide was reported for the first time by Osman 
and Rajkumar in two independent phase 2 trials [31] in 2001. The combination of 
thalidomide (100–200 mg/day), doxorubicin (36 mg/m2 on the first day of each 28-day 
cycle,) and dexamethasone (40 mg daily on days 1–4, 9–12, and 17–20 of each cycle) 
produced symptomatic deep venous thrombosis in four of the first 15 enrolled patients 
(27%) and the trial was therefore stopped. The other phase 2 trial combined thalidomide and 
dexamethasone for the treatment of patients with newly diagnosed myeloma at the Mayo 
Clinic. Seven percent (3/45) had thrombotic events. Cavo [32] and Rajkumar [33] in another 
www.intechopen.com
 
Thrombosis Associated with Immunomodulatory Agents in Multiple Myeloma 117 
two phase 3 trials confirmed the preliminary observations of increased incidence of VTE in 
newly diagnosed MM treated with thalidomide plus dexamethasone (16 and 17% of VTEs). 
(table 1 below). 
 
Regimen n Status of disease Incidence (%) 
Thalidomide in monotherapy    
     Barlogie, 2001 26 169 RR < 2 
     Bennet, 2001 27   326 RR 4.6 
     Rajkumar, 2002 28 31 RR 3.4 
     Tosi, 2002 29 65 RR 1.5 
     Weber, 2002 30 28 ND 3 
Thalidomide / Dexamethasone    
     Cavo, 2004 32 71 ND 16 
     Rakjumar, 2006 33 103 ND 17 
     Palumbo, 2004 34 120 RR 2 
     Dimopoulos, 2001 35 44 RR 7 
Thalidomide / Melphalan / Prednisone    
     Palumbo, 2006 36 129 ND 20 
     Facon, 2007 37 125 ND 12 
Thalidomide / Melphalan / 
Dexamethasone 
   
     Dimopoulos 2006 38 50 ND 9 
Thalidomide / Dexamethasone / CTX    
     Sidra, 2006 39 62 ND / RR 3.2 
     García-Sanz, 2004 40 71 RR 7 
     Dimopoulos, 2004 41 53 RR 4 
     Kropff, 2003 42 60 RR 9 
     Moehler, 2003 43 56 RR 7 
Thalidomide / Chemotherapy    
     Baz, 2005 44 35 ND/RR 58 
     Zangari, 2004 3 87 ND 34 
     Zangari, 2002 45 232 RR 16 
     Barlogie, 2006 46 323 ND 34 
     Schutt, 2005 47 31 ND 26 
     Zervas, 2004 48 39 ND 10 
RR: refractory / relapsed; ND: newly diagnosed. 
Table 1. Incidence of thalidomide-associated venous thromboembolism without VTE 
prophylaxis 
Similarly, when thalidomide was combined with melphalan and steroids, the incidence of 
VTE was 9–20% in newly diagnosed elderly patients [36-38]. In all of these studies, the major 
risk of thrombosis occurs early after initiation of the treatment, when the tumor load is 
maximal. Thus, this complication may be related to the release of thrombogenic factors from 
myeloma cells rather than to cumulative drug exposure [49]. 
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A meta-analysis of studies of thalidomide in MM, which involved 3,322 patients, showed 
that patients receiving thalidomide were 2.1 times as likely to have a VTE event compared 
with those who were not receiving thalidomide (p<0.01). Those receiving thalidomide plus 
dexamethasone were 3.1 times as likely to have a VTE event (p<0.01), and those receiving 
thalidomide in addition to other chemotherapy agents were 1.5 times as likely to have a VTE 
event (p<0.01) [2]. 
The pathogenesis of thalidomide-associated thrombosis has not yet been established. 
Zangari et al. [10] tested for hypercoagulability in 62 newly diagnosed MMs, and found that 
DVT was more frequent in those patients with acquired APC resistance (36 vs. 15%, p<0.04). 
The pre-existing elevated factor VIII coagulant activity and von Willebrand factor antigen 
have also been related with thalidomide-associated thrombosis [50]. In an experimental 
model, Kausahal et al. demonstrated that the addition of thalidomide to uninjured arterial 
endothelium did not cause any appreciable change, whereas thalidomide added to 
adriamycin-injured (8–24 h) endothelial cells resulted in endothelial dysfunction by altering 
the expression of PAR-1 in injured endothelium [51]. 
Cases of VTE that began shortly after the initiation of treatment with recombinant human 
erythropoietin in patients who had been receiving thalidomide for some time have been 
reported [52]. However, another study found no apparent increased risk of thrombosis in 
199 cases of myeloma given thalidomide with or without erythropoietin. Of the 49 patients 
receiving both drugs, 8.1% developed thrombosis compared with 9.3% of the 150 patients on 
thalidomide who did not receive erythropoietin [53]. 
The genetic susceptibility to developing a VTE in response to thalidomide therapy has been 
also evaluated. The lack of a strong association with genetic variations in the coagulation 
cascade, such as factor V Leiden or G20210A prothrombin mutation, suggests that VTE risk 
is mediated via alternative mechanisms. Johnson et al [54] identified 18 SNPs, using a 
custom-built molecular inversion probe (MIP)-based single nucleotide polymorphism (SNP) 
chip. There were two “response to stress” groups: a response to DNA damage group, 
including CHEK1, XRCC5, LIG1, ERCC6, DCLRE1B and PARP1, and a cytokine response 
group containing NFKB1, TNFRSF17, IL12B and LEP. A third apoptosis-related group with 
CASP3, PPARD and NFKB1 was also found.  
Interestingly, no thromboembolic events were observed in a group of 30 patients with 
relapsed MM treated with a bortezomib, melphalan, prednisone and thalidomide (VMPT) 
combination despite the absence of any anticoagulant prophylaxis [55]. A recent review of 
phase 3 trials of bortezomib- and/or IMiD-based therapy in frontline MM, together with 
other studies of novel combination regimens concluded that bortezomib-based regimens 
were typically associated with DVT/PE rates of ≤ 5%, similar to those seen with melphalan-
prednisone and dexamethasone, whereas IMiD-based bortezomib-free regimens were 
generally associated with higher rates [56]. These results suggested the existence of a 
protective effect of coadministration of thalidomide or lenalidomide with bortezomib [57-
58]. Zangari et al prospectively described in vivo effects of bortezomib from routine tests of 
blood coagulation and platelet function in treated MM patients. This pilot clinical trial 
showed in vivo that even a short exposure to bortezomib can affect platelet function. Platelet 
aggregation was reduced after bortezomib infusion with most of the commonly agonists 
used (ADP, epinephrine and ristocetin) on both days of treatment [59].  
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The majority of thrombotic events described in patients receiving treatment with 
thalidomide have been venous, but occasional arterial thrombotic events have also been 
reported [60-63]. In a prospective analysis of arterial thrombosis risk, the incidence of 
arterial thrombosis in patients with newly diagnosed MM treated with three cycles of 
thalidomide, doxorubicin and dexamethasone (TAD group) was 4.5%.  However, the true 
incidence of arterial thrombosis could have been underestimated in the TAD group due to 
prophylactic use of LMWH. High factor VIII:C levels, possibly reflecting disease activity, 
could contribute to the risk of arterial thrombosis especially in patients with known 
cardiovascular risk factors [64].  
4. Lenalidomide and thrombosis 
Lenalidomide, a more potent immunomodulatory derivative of thalidomide, was designed 
to increase the anti-myeloma efficacy of thalidomide, while possibly reducing side effects 
like neuropathy and thrombosis. However, although neuropathy is not an important 
lenalidomide-related side effect, thrombosis continues to be one of the most important side 
effects, especially when lenalidomide is given in combination with dexamethasone or 
chemotherapy (table 2). 
 
Regimen n Status of disease Incidence (%) 
Lenalidomide in monotherapy    
     Richardson, 2009 65 222 RR 4 
Lenalidomide / Dexamethasone    
     Dimopoulos, 2007 66 176 RR 11.4 
     Weber, 2007 67 177 RR 14.7 
     Zonder, 2005 68 38 ND 75 
     Rajkumar 2010 69 223 ND 26 
Lenalidomide / Dexamethasone Low Dose    
     Rajkumar, 2010 69 222 ND 12 
Lenalidomide / Dexamethasone / 
Bortezomib 
   
     Richardson, 2010 70 66 ND 6 
RR: refractory / relapsed; ND: newly diagnosed. 
Table 2. Incidence of lenalidomide-associated venous thromboembolism without VTE 
prophylaxis 
In two large phase 3 trials comparing lenalidomide plus dexamethasone to 
dexamethasone alone without mandated thromboprophylaxis in patients with RRMM, the 
incidences of VTE in the LD arm were 11.4 and 14.7%, compared with 4.6 and 3.4% in the 
DEX alone arm [66-67]. The incidence was even higher in patients with newly diagnosed 
MM (up to 75%) who were treated with lenalidomide plus dexamethasone [68]. In all 
these trials conducted in RR and newly diagnosed MM patients, dexamethasone was 
given at high dose (three pulses of 40 mg for 4 days, total amount per cycle: 480 mg). 
Interestingly, the rate of VTE was significantly lower when lenalidomide was combined 
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with low-dose dexamethasone (40 mg weekly; total dose per cycle: 160mg) compared with 
high-dose (26 vs. 12%, p=0.0003) [69]. 
Similar to thalidomide, low rates of VTE have been reported in MM patients treated with 
lenalidomide in combination with bortezomib. In a phase 1/2 study of lenalidomide plus 
dexamethasone and bortezomib without thromboprophylaxis, thrombosis was rare (6% 
overall) [70]. 
The role of ESA and lenalidomide in thrombotic risk is controversial. An increased 
thrombotic risk has been observed in patients who received concomitant ESA with 
lenalidomide plus dexamethasone [71], although a third study showed no impact of ESA 
[72]. 
5. Pomalidomide and thrombosis 
Pomalidomide (CC4047) is a new IMiD with high in vitro potency. In a phase 1 trial 
evaluating CC-4047 alone in 24 patients with RRMM, 4 (17%) developed a TEE during the 
first year of therapy [73]. Thromboprophylaxis was given in the phase 2 studies of 
pomalidomide and low-dose dexamethasone [74-78]. 
6. Prophylaxis of TEE-related IMiDs 
Patients with MM being treated with IMiDs-based combinations should receive 
thromboprophylaxis [79-80]. There are data showing benefit of using low-molecular-weight 
heparin (LMWH), full-dose warfarin and daily aspirin in myeloma patients receiving IMiDs 
drugs [3, 44, 81]. However, fixed-dose warfarin (1 mg/d) was ineffective in reducing the 
VTE rate [3, 36]. Currently, outpatient VTE prophylaxis is recommended by the Italian 
Association of Medical Oncology, the National Comprehensive Cancer Network, the 
American Society of Clinical Oncology, the French National Federation of the League of 
Centers Against Cancer and the European Society of Medical Oncology only for medical 
oncology patients receiving highly thrombogenic thalidomide- or lenalidomide-based 
combination chemotherapy regimens [80]. 
The 2008 International Myeloma Working Group consensus statement on VTE prophylaxis 
in myeloma patients receiving thalidomide or lenalidomide [81], recommends a prophylaxis 
strategy according to a risk-assessment model. Individual risk factors for VTE associated 
with thalidomide and lenalidomide therapy include: advanced age, a history of VTE, an 
indwelling central venous catheter, comorbid conditions (e.g, infections, diabetes, cardiac 
disease, etc), current or recent immobilization, recent surgery and inherited thrombophilic 
abnormalities. Myeloma-related risk factors include diagnosis and hyperviscosity. Therapy-
related risk factors include high-dose dexamethasone, doxorubicin or multiagent 
chemotherapy in combination with thalidomide or lenalidomide, but not with bortezomib. 
The panel recommends aspirin for patients with ≤1 risk factor for VTE. LMWH (equivalent 
to enoxaparin 40 mg per day) is recommended for those with two or more 
individual/myeloma-related risk factors. LMWH is also recommended for all patients 
receiving concurrent high-dose dexamethasone or doxorubicin. Full-dose warfarin targeting 
a therapeutic INR of 2-3 is an alternative to LMWH, although little has been published about 
this strategy (see figure 1 below ). 
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Fig. 1. International Myeloma Working Group consensus statement on VTE prophylaxis in 
myeloma patients receiving thalidomide or lenalidomide (2008). 
Two direct comparison trials between thromboprophylaxis agents have recently been 
conducted. In the first phase 3 Italian Myeloma Network GIMEMA study [82], which 
prospectively assessed the impact of LMWH, aspirin or low-dose warfarin in newly 
diagnosed patients receiving thalidomide as part of either VMPT, VTD or TD regimens, the 
risk of VTE was similar in all three thromboprophylactic therapies after 6 months of follow 
up (5.0, 6.4 and 8.2%, respectively), and all were considered likely to be effective. 
The second phase 3 trial compared the efficacy and safety of thromboprophylaxis with low-
dose aspirin (ASA) or low-molecular-weight heparin (LMWH) in newly diagnosed MM 
patients, treated with lenalidomide and low-dose dexamethasone induction and melphalan-
prednisone lenalidomide consolidation. The incidence of VTE was 2.27% in the ASA group 
and 1.20% in the LMWH group. The authors concluded that aspirin could be an effective 
and less expensive alternative to LMWH thromboprophylaxis during treatment with 
lenalidomide [83]. 
However, some questions remain unanswered: the outcome of the use of 
thromboprophylaxis in patients already in remission receiving thalidomide or lenalidomide 
as maintenance therapy during prolong periods of time is not well understood. A recent 
meta-analysis of the use of thalidomide as maintenance after autologous transplantation 
found the incidence of thromboembolic events to be 4–6%, and the risk of thromboembolism 




Before treatment with IMiDs
Evaluating risk factors
0 – 1 Risk factor > 1 Risk factor High - dose dexamethasone
Doxorubicin
multi-chemotherapy
Aspirin 81 - 325 mg / day HBPM: enoxaparin 40 mg/d
dalteparin 5000 UI/d
fondaparinux 2.5 mg/d
At least 4 – 6 months
More than 4 – 6 months if:  persistence of risk factors
apparition of new risk factors
risk factor: Obesity, previous venous thromboembolism, central venous catheter or pacemaker, cardiac disease, chronic renal disease, diabetes, 
acute infection, immobilization, general surgery, anesthesia, trauma, erythropoietin, blood clotting disorders, myeloma at diagnosis and hyperviscosity
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was 1.95 times that of patients who did not receive thalidomide [84]. The use of ASA for a 
longer period may reduce the risk of late thromboembolism. Future studies should address 
this possibility. 
7. Management of IMiD-associated VTE 
No studies or guidelines are available to guide treatment of established 
thalidomide/lenalidomide-associated VTE. Although the use of LMWH has improved VTE 
management in patients with solid tumors [85], no similar experience has been built up in 
patients with MM. The recommended treatment for thalidomide- or lenalidomide-
associated thrombosis is either LMWH or warfarin. However, the use of LMWH is more 
attractive because of the lack of need for laboratory monitoring and the reduced variability 
(compared with warfarin) caused by interference from drugs and food. Also, in patients 
with solid tumors, LMWH administered for 6 months after a first VTE episode (1 month at 
full dose and 5 months at approximately 75% of the full dose) has proved to be safe and 
superior to warfarin in preventing VTE recurrence [85]. However, the optimal duration of 
anticoagulation therapy in oncology patients remains controversial. 
The optimal doses of the most commonly used LMWH are 100 U/kg every 12 h or 200 U/kg 
daily for dalteparin, 1 mg/kg every 12 h or 1.5 mg/kg daily for enoxaparin, and 86 U/kg 
every 12 h or 171 U/kg daily for nadroparin. In patients with a high risk of hemorrhage 
(thrombocytopenia or renal failure), association of monitoring of peak anti-factor Xa levels 
to maintain a range of 0.5 to 1.0 IU/mL could be very attractive. In addition, a reduction of 
50% of the therapeutic dose of LMWH for platelet counts less than 50 x109/µL, and a 
temporary discontinuation of LMWH for platelet counts less than 20,000 x109/µL can be 
performed [86]. Also, UFH followed by warfarin remains a sensible alternative for VTE 
treatment in patients with CrCl <30 ml/min [87]. 
Zangari et al reported the treatment of 14 patients who developed thalidomide-related VTE. 
In 75% of them, administration of thalidomide was safely resumed after appropriate 
anticoagulation therapy was initiated. This consisted of low-molecular-weight heparin 
followed by warfarin, the target being the international normalized ratio of 2.5 to 3. Both 
anticoagulant and thalidomide treatments were continued as long as they were clinically 
indicated [88].  
Alternative anti-myeloma treatment with an IMiS-free scheme should be seriously 
considered in patients who develop a VTE receiving LMWH or warfarin therapy with an 
appropriate INR [89]. However, if the use of IMiDs which produced the VTE is absolutely 
necessary, an alternative anticoagulant scheme could be used. In this setting, in patients 
with cancer-associated thrombosis while on warfarin therapy, with an appropriate INR, a 
recommended practice is to switch them to LMWH because it is more efficacious than 
warfarin [90]. On the other hand, dose escalation appears to be effective in patients who 
develop a cancer-associated thrombosis while on LMWH. In a small cohort study of 
oncology patients with recurrent thrombosis while on LMWH or warfarin, escalating the 
dose of LMWH by 20–25% or switching to LMWH, respectively, prevented further 
thrombotic episodes [91]. 
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